コンテンツへスキップ
Merck

R1000600

リスペリドン

European Pharmacopoeia (EP) Reference Standard

別名:

R 64,766

ログインで組織・契約価格をご覧ください。

サイズを選択してください


この商品について

実験式(ヒル表記法):
C23H27FN4O2
CAS番号:
分子量:
410.48
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします

InChI

1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

SMILES string

CC1=C(CCN2CCC(CC2)c3noc4cc(F)ccc34)C(=O)N5CCCCC5=N1

InChI key

RAPZEAPATHNIPO-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

risperidone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

類似した製品をお探しですか? 訪問 製品比較ガイド

General description

Risperidone is a new central 5-hydroxytryptamine2 and dopamine D2 antagonist. It is used to treat agitation, aggression,and psychosis caused during demnetia. It is a neuroleptic drug. It is also an atypical antipsychotic drug which is used for treating schizophrenia.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Risperidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

この製品は発行元の薬局方による供給としてお届けします。現在の単位量については、EDQM reference substance catalogueをご覧ください。

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

保管分類

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

R1000600: + R1000600-1EA: + R1000600-50MG:

jan


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Vina M Goghari et al.
Schizophrenia research, 149(1-3), 149-155 (2013-07-09)
Atypical antipsychotic medications generally maintain or increase gray matter amount and functioning. First-episode psychosis patients have lower gray matter volume in the middle frontal gyrus, as well as worse performance on spatial working memory tasks compared to controls. This study
Cécile Danel et al.
Carbohydrate polymers, 92(2), 2282-2292 (2013-02-13)
The interactions between nine drugs (baclofen, bupivacaine, chlorpheniramine, ketoconazole, paliperidone, promethazine, propranolol, risperidone and verapamil) and six cyclodextrins (α-CD, β-CD, γ-CD, HP-β-CD, HP-γ-CD and Me-β-CD) or six polymers of cyclodextrins (polyα-CD, polyβ-CD, polyγ-CD, polyHP-β-CD, polyHP-γ-CD and polyMe-β-CD) were studied by
Yvonne Freund-Levi et al.
Dementia and geriatric cognitive disorders, 38(3-4), 234-244 (2014-06-28)
To examine the effects of galantamine and risperidone on agitation in patients with dementia. A total of 100 patients with dementia and neuropsychiatric symptoms (mean age ± SD: 78.6 ± 7.5 years; 67% female) were included in this 12-week, randomized
Christian Spang Pedersen et al.
Behavioural brain research, 273, 63-72 (2014-07-30)
Schizophrenia is a severe psychiatric disorder characterized by three symptom domains, positive (hallucinations, obsession), negative (social withdrawal, apathy, self-neglect) and cognitive (impairment in attention, memory and executive function). Whereas current medication ameliorates positive symptomatology, negative symptoms as well as cognitive
Jérôme A J Becker et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(9), 2049-2060 (2014-03-13)
The etiology of Autism Spectrum Disorders (ASDs) remains largely unknown. Identifying vulnerability genes for autism represents a major challenge in the field and allows the development of animal models for translational research. Mice lacking the mu opioid receptor gene (Oprm1(-/-))

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)